Want to see HK:1952 full AI Analyst Report?
Everest Medicines Ltd. (1952) Ratios
Everest Medicines Ltd. Ratios
HK:1952's free cash flow for Q2 2026 was $-165.48M. For the 2026 fiscal year, HK:1952's free cash flow was decreased by $-29.22M and operating cash flow was $-136.25M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.89 | 2.54 | 8.36 | 3.92 | 9.95 |
| Quick Ratio | 4.77 | 2.52 | 8.29 | 3.91 | 9.94 |
| Cash Ratio | 3.96 | 1.11 | 1.74 | 0.56 | 9.77 |
| Solvency Ratio | -0.09 | -1.05 | -0.95 | -0.21 | -1.30 |
| Operating Cash Flow Ratio | -0.16 | -0.86 | -2.56 | -1.33 | -2.70 |
| Short-Term Operating Cash Flow Coverage | -1.48 | -1.45 | -33.94 | -2.73 | 0.00 |
| Net Current Asset Value | $ 1.85B | $ 1.13B | $ 1.70B | $ 2.45B | $ 1.93B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.12 | 0.09 | 0.08 | 0.07 |
| Debt-to-Equity Ratio | 0.17 | 0.14 | 0.10 | 0.09 | 0.08 |
| Debt-to-Capital Ratio | 0.15 | 0.12 | 0.09 | 0.09 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.13 | 0.01 | 0.08 | 0.01 | 0.06 |
| Financial Leverage Ratio | 1.29 | 1.22 | 1.16 | 1.17 | 1.13 |
| Debt Service Coverage Ratio | 1.09 | -1.36 | -16.29 | -0.46 | -201.99 |
| Interest Coverage Ratio | -17.04 | -50.34 | -40.45 | -45.93 | -213.11 |
| Debt to Market Cap | 0.08 | 0.04 | 0.08 | 0.10 | 0.05 |
| Interest Debt Per Share | 2.84 | 1.86 | 1.70 | 1.82 | 1.67 |
| Net Debt to EBITDA | 9.64 | 0.46 | 0.02 | -0.22 | 2.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 69.25% | 74.84% | 72.67% | 63.69% | 57.41% |
| EBIT Margin | -20.15% | -110.41% | -652.26% | -1889.34% | -1859079.63% |
| EBITDA Margin | -10.98% | -94.82% | -591.29% | -1554.97% | -1801442.59% |
| Operating Profit Margin | -22.63% | -158.07% | -740.67% | -2007.50% | -1900614.81% |
| Pretax Profit Margin | -35.06% | -147.36% | -670.57% | -1933.04% | -1867998.15% |
| Net Profit Margin | -17.45% | -147.36% | -670.57% | -1933.11% | -1867998.15% |
| Continuous Operations Profit Margin | -17.45% | -147.36% | -670.57% | -1933.11% | -1867998.15% |
| Net Income Per EBT | 49.76% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 154.92% | 93.23% | 90.54% | 96.29% | 98.28% |
| Return on Assets (ROA) | -4.35% | -21.00% | -14.63% | -3.74% | -15.18% |
| Return on Equity (ROE) | -5.61% | -25.57% | -17.00% | -4.37% | -17.12% |
| Return on Capital Employed (ROCE) | -6.28% | -26.82% | -17.04% | -4.47% | -16.10% |
| Return on Invested Capital (ROIC) | -3.16% | -24.00% | -16.92% | -4.15% | -16.03% |
| Return on Tangible Assets | -6.27% | -38.51% | -25.99% | -5.88% | -26.58% |
| Earnings Yield | -2.68% | -7.14% | -14.24% | -5.41% | -12.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.11 | 1.94 | 2.53 | 2.45 | 1.10 |
| Payables Turnover | 2.57 | 3.86 | 0.70 | 0.04 | 0.00 |
| Inventory Turnover | 6.28 | 12.63 | 1.82 | 0.40 | 0.05 |
| Fixed Asset Turnover | 2.59 | 1.09 | 0.18 | 0.02 | 0.00 |
| Asset Turnover | 0.25 | 0.14 | 0.02 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.87 | 0.41 | 0.05 | 0.01 | 0.00 |
| Cash Conversion Cycle | 33.65 | 122.61 | -173.14 | -7385.63 | -1351930.32 |
| Days of Sales Outstanding | 117.37 | 188.37 | 144.51 | 148.77 | 331.20 |
| Days of Inventory Outstanding | 58.09 | 28.91 | 200.92 | 914.43 | 7093.70 |
| Days of Payables Outstanding | 141.82 | 94.67 | 518.57 | 8448.83 | 1359355.22 |
| Operating Cycle | 175.46 | 217.28 | 345.43 | 1063.20 | 7424.90 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.33 | -2.12 | -2.46 | -3.88 | -2.49 |
| Free Cash Flow Per Share | -0.52 | -2.32 | -3.31 | -5.34 | -5.82 |
| Dividend Paid and CapEx Coverage Ratio | -1.76 | -10.39 | -2.89 | -2.67 | -0.75 |
| Capital Expenditure Coverage Ratio | -1.76 | -10.39 | -2.89 | -2.67 | -0.75 |
| Operating Cash Flow Coverage Ratio | -0.12 | -1.18 | -1.51 | -2.16 | -1.50 |
| Operating Cash Flow to Sales Ratio | -0.06 | -0.96 | -6.11 | -90.35 | -13517.33 |
| Free Cash Flow Yield | -1.55% | -5.11% | -17.46% | -34.78% | -21.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -37.32 | -14.01 | -7.02 | -18.47 | -7.91 |
| Price-to-Sales (P/S) Ratio | 6.51 | 20.64 | 47.08 | 357.07 | 147707.27 |
| Price-to-Book (P/B) Ratio | 2.09 | 3.58 | 1.19 | 0.81 | 1.35 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -64.49 | -19.58 | -5.73 | -2.88 | -4.68 |
| Price-to-Operating Cash Flow Ratio | -101.06 | -21.47 | -7.71 | -3.95 | -10.93 |
| Price-to-Earnings Growth (PEG) Ratio | 0.51 | -0.70 | -0.03 | 0.24 | 0.09 |
| Enterprise Value Multiple | -49.67 | -21.31 | -7.95 | -23.18 | -5.98 |
| Enterprise Value | 9.31B | 14.28B | 5.92B | 4.61B | 5.82B |
| EV to EBITDA | -49.67 | -21.31 | -7.95 | -23.18 | -5.98 |
| EV to Sales | 5.45 | 20.21 | 46.98 | 360.50 | 107799.51 |
| EV to Free Cash Flow | -54.01 | -19.17 | -5.72 | -2.90 | -3.41 |
| EV to Operating Cash Flow | -84.63 | -21.01 | -7.69 | -3.99 | -7.97 |
| Tangible Book Value Per Share | 9.62 | 5.67 | 7.81 | 10.89 | 10.37 |
| Shareholders’ Equity Per Share | 15.86 | 12.69 | 15.87 | 19.00 | 20.09 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.49 | 0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 5.10 | 2.20 | 0.40 | 0.04 | 0.00 |
| Net Income Per Share | -0.89 | -3.24 | -2.70 | -0.83 | -3.44 |
| Tax Burden | 0.50 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.74 | 1.33 | 1.03 | 1.02 | 1.00 |
| Research & Development to Revenue | 0.30 | 0.75 | 4.29 | 63.30 | 11359.87 |
| SG&A to Revenue | 0.62 | 1.07 | 1.31 | 21.62 | 4494.00 |
| Stock-Based Compensation to Revenue | 0.08 | 0.13 | 0.58 | 16.14 | 4166.30 |
| Income Quality | 0.37 | 0.65 | 0.91 | 4.67 | 0.72 |
Currency in CNY
